Literature DB >> 17826642

The 212A variant of the APJ receptor gene for the endogenous inotrope apelin is associated with slower heart failure progression in idiopathic dilated cardiomyopathy.

Riccardo Sarzani1, Cinzia Forleo, Francesca Pietrucci, Alessandro Capestro, Elli Soura, Pietro Guida, Sandro Sorrentino, Massimo Iacoviello, Roberta Romito, Paolo Dessì-Fulgheri, Mariavittoria Pitzalis, Alessandro Rappelli.   

Abstract

BACKGROUND: Idiopathic dilated cardiomyopathy (IDC) has multiple genetic and acquired causes. Apelin is an endogenous peptide that increases cardiac inotropism through his APJ receptor. No data are available concerning the APJ gene mutations responsible for IDC or on the role of APJ receptor gene variants in predicting heart failure (HF) progression. METHODS AND
RESULTS: We prospectively evaluated 202 consecutive patients with IDC and 202 matched controls: 90 were screened for APJ gene mutations and all 202 were genotyped for G212A and A445C APJ receptor polymorphisms. No mutations were found within the coding or untranslated regions of the APJ receptor, and no differences in allelic or genotype frequencies were observed comparing patients with a healthy control population. The correlations between APJ receptor polymorphisms and HF progression were assessed. During a median follow-up of 37 months, 35 patients experienced HF progression. Univariate analysis showed that patients carrying at least 1 copy of 212A had a significantly lower risk for HF-related events than those who were homozygous for the G212 variant, and multivariate analysis confirmed that it was significantly related to a more favorable prognosis.
CONCLUSIONS: APJ is unlikely to be a gene causing IDC, but the independent correlation between the 212A allele and a better prognosis suggests that it might act as a modifier gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826642     DOI: 10.1016/j.cardfail.2007.04.002

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  8 in total

Review 1.  Apelin and insulin resistance: another arrow for the quiver?

Authors:  Shiming Xu; Philip S Tsao; Patrick Yue
Journal:  J Diabetes       Date:  2011-09       Impact factor: 4.006

2.  Modulation of the apelin/APJ system in heart failure and atherosclerosis in man.

Authors:  Sarah L Pitkin; Janet J Maguire; Rhoda E Kuc; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Association of genetic variants in the apelin-APJ system and ACE2 with blood pressure responses to potassium supplementation: the GenSalt study.

Authors:  Qi Zhao; Dongfeng Gu; Tanika N Kelly; James E Hixson; Dabeeru C Rao; Cashell E Jaquish; Jing Chen; Jianfeng Huang; Chung-Shiuan Chen; C Charles Gu; Paul K Whelton; Jiang He
Journal:  Am J Hypertens       Date:  2010-03-11       Impact factor: 2.689

4.  Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats.

Authors:  Qi Zhang; Fanrong Yao; Mohan K Raizada; Stephen T O'Rourke; Chengwen Sun
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

5.  Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges.

Authors:  Seyyed M R Kazemi-Bajestani; Vaibhav B Patel; Wang Wang; Gavin Y Oudit
Journal:  Cardiol Res Pract       Date:  2012-05-13       Impact factor: 1.866

Review 6.  Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.

Authors:  Peiran Yang; Janet J Maguire; Anthony P Davenport
Journal:  Trends Pharmacol Sci       Date:  2015-07-01       Impact factor: 14.819

Review 7.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

8.  Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues.

Authors:  Wang Wang; Shaun M K McKinnie; Vaibhav B Patel; George Haddad; Zuocheng Wang; Pavel Zhabyeyev; Subhash K Das; Ratnadeep Basu; Brent McLean; Vijay Kandalam; Josef M Penninger; Zamaneh Kassiri; John C Vederas; Allan G Murray; Gavin Y Oudit
Journal:  J Am Heart Assoc       Date:  2013-07-01       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.